Navigation Links
Telik Announces Third Quarter 2011 Financial Results
Date:11/3/2011

PALO ALTO, Calif., Nov. 3, 2011 /PRNewswire/ -- Telik, Inc. (Nasdaq: TELK) today reported a net loss of $2.8 million, or $0.05 per share, for the third quarter ended September 30, 2011, compared with a net loss of $4.7 million, or $0.09 per share, for the comparable period in 2010.

For the quarter ended September 30, 2011, total operating costs and expenses were $2.9 million, compared with $4.7 million in the third quarter of 2010.  Operating expenses in the 2011 third quarter included stock-based compensation expense of approximately $0.5 million.  Operating expenses were approximately 39% lower in the third quarter of 2011 compared with the same period in 2010, primarily due to lower headcount, clinical development and facility expenses.

For the nine months ended September 30, 2011, Telik reported a net loss of $9.5 million, or $0.18 per share, compared with a net loss of $14.9 million, or $0.28 per share, for the same period in 2010.  Total operating expenses for the first nine months of 2011 were $9.6 million, compared with $15.1 million for the same period in 2010.  Operating expenses in the first nine months of 2011 included approximately $1.2 million in stock-based compensation expense.  The reduction in operating expenses of approximately 37% in the first nine months of 2011 compared with the same period in 2010 was primarily due to lower headcount, reduced clinical trial expenses, lower stock-based compensation and lower facility costs.

At September 30, 2011, Telik had $14.0 million in cash, cash equivalents and investments including restricted investments, compared to $24.1 million at December 31, 2010.

About Telik

Telik, Inc. of Palo Alto, CA, is a clinical stage drug development company focused on discovering and developing small molecule drugs to treat cancer.  The company's most advanced drug candid
'/>"/>

SOURCE Telik, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Telik Announces Publication of a Report of Complete Response of G-CSF Resistent Severe Idiopathic Chronic Neutropenia Following Treatment with Telintra®
2. Telik Announces Ezatiostat (Telintra®) Preclinical Presentation at the 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
3. Telik Announces Initiation of a Phase 2b Clinical Trial of Telintra® (Ezatiostat HCL) in Patients With Low to Intermediate-1 Risk Non-Deletion (5q) Myelodysplastic Syndrome
4. Telik Announces Publication in the Journal Cancer of a Phase 2 Randomized Multicenter Study of Two Extended Dosing Schedules of Oral Ezatiostat in Low to Intermediate-1 Risk Myelodysplastic Syndrome
5. Telik Announces First Quarter 2011 Financial Results
6. Telik Announces Presentation of New Data on the Characterization of Novel Ezatiostat (TELINTRA®, TLK199) Analogs at American Association for Cancer Research Annual Meeting
7. Telik Announces Presentation and Webcast at 10th Annual Needham Healthcare Conference
8. Telik Announces Fourth Quarter and 2010 Year End Financial Results and 2011 Financial Guidance
9. Telik Announces Presentation and Webcast at 13th Annual BIO CEO & Investor Conference
10. Telik Announces Presentation at American Society of Hematology Annual Meeting
11. Telik Announces Third Quarter 2010 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/27/2015)... CTI BioPharma Corp. (NASDAQ and MTA: CTIC) announced today ... financial results on Thursday, August 6, 2015, after the ... members of the management team will host a webcast ... general corporate update at 4:30 p.m. EDT (1:30 p.m. ... follows: Thursday, August 6 1:30 p.m. PDT/4:30 ...
(Date:7/27/2015)... PARIS , July 28, 2015   Regeneron ... into a new global collaboration to discover, develop and ... of immuno-oncology. As part of the agreement, the two ... 1 (PD-1) inhibitor currently in Phase 1 testing and ... therapeutic candidates based on ongoing, innovative preclinical programs. ...
(Date:7/27/2015)... WESTLAKE VILLAGE, Calif. , July 27, ... and KYTHERA Biopharmaceuticals, Inc. (NASDAQ: KYTH ) today ... granted early termination of the waiting period under the ... respect to Allergan,s pending acquisition of KYTHERA.  ... July 6, 2015, each of Allergan and KYTHERA filed ...
Breaking Medicine Technology:CTI BioPharma to Report Second Quarter 2015 Financial Results on August 6, 2015 2Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration 2Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration 3Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration 4Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration 5Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration 6Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration 7Regeneron and Sanofi Launch Major New Immuno-Oncology Collaboration 8Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 2Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 3Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 4Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 5Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 6Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 7Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 8Allergan and KYTHERA Announce Early Termination of Hart-Scott-Rodino Waiting Period for Allergan's Pending Acquisition of KYTHERA 9
(Date:7/28/2015)... , ... July 28, 2015 , ... ... announced HeartPlace will be expanding their cloud presence to support their rapidly growing ... in North Texas, has been serving the Dallas/Fort Worth area for almost 50 ...
(Date:7/28/2015)... ... July 28, 2015 , ... Maryland Brain & Spine ... and, along with it, more service offerings, updated treatment techniques, and additional state-of-the art ... pain management and minimally invasive surgical treatment of brain and spine conditions. , ...
(Date:7/28/2015)... ... , ... Please join us for the 5th Annual Step for Hope 5K Run/Walk ... and Lies Road in Carol Stream. All are welcome. , Now in its 5th ... help to support individuals and families affected by a brain aneurysm. , “We look ...
(Date:7/28/2015)... ... ... Advanced Fertility Center of Texas (AFCT) has hosted the EMBCOL office ... a Reproductive Laboratory Director at AFCT, was one of the founders of EMBCOL and ... who is credited with the discovery of intra-cytoplasmic sperm injection (ICSI) , which ...
(Date:7/28/2015)... ... July 28, 2015 , ... One of ... Runner’s World Magazine, is plantar fasciitis . Zensah, the Miami-based compression brand, ... by a professional athletic trainer, the Zensah Ankle Support’s primary benefits include helping ...
Breaking Medicine News(10 mins):Health News:HeartPlace Announces Cloud Expansion with VAZATA 2Health News:HeartPlace Announces Cloud Expansion with VAZATA 3Health News:Maryland Brain & Spine Announces New Specialty, New Name 2Health News:Maryland Brain & Spine Announces New Specialty, New Name 3Health News:Maryland Brain & Spine Announces New Specialty, New Name 4Health News:5th Annual Step for Hope 5K Run/Walk Event in Carol Stream, IL to Benefit Renowned Brain Aneurysm Foundation 2Health News:Advanced Fertility Center of Texas Is Proud to Announce That Our Lab Director Has Been Re-elected as The American College of Embryology President 2Health News:Zensah Releases Compression Sleeve To Relieve Ankle Pain and Plantar Fasciitis 2
... caffeine in coffee, tea or soft drinks increases blood ... may undermine efforts to control their disease, say scientists ... technology that measured participants glucose (sugar) levels on a ... psychologist at Duke and the lead author of the ...
... assisted living facility in violation of "Nicole,s Law" designed to ... protect vulnerable ... Atria Senior Living? That,s what members of the Campaign to Improve,Assisted ... facility at 15 Stevens Street in Andover was found in,violation of ...
... EPA campaign in January heightens awareness, tries to reduce ... an invisible radioactive gas that seeps into homes through ... monoxide poisoning, says the U.S. Environmental Protection Agency. , ... has designated January as National Radon Action Month. , ...
... people in Western society are suffering from auto-immune diseases. ... first important step in the search for targeted medicines. ... Universiteit Leuven joined forces and have elucidated the function ... They are the first to show that MALT1 ...
... how a particular family of diseases are passed down from ... severity of the disease differing widely. The research, funded by ... a child,s risk of developing a mitochondrial disease which can ... All human and animal cells contain many mitochondria, which are ...
... On January 23rd, Public,Citizen, a consumer group, filed ... and,Administration (FDA) requesting labeling changes for botulinum toxins,marketed ... and recorded studies in peer-reviewed journals have,documented the ... Surgery (ASAPS), the leading organization of board-certified,plastic surgeons ...
Cached Medicine News:Health News:Cutting caffeine may help control diabetes 2Health News:Activists Raise Alarm for Seniors, Deliver Carbon Monoxide Detectors to Atria Marland Place 2Health News:Radon Gas More Deadly Than Carbon Monoxide Poisoning 2Health News:A major step toward a more targeted treatment for auto-immune diseases? 2Health News:Mitochondrial 'bottleneck' cracked 2Health News:The American Society for Aesthetic Plastic Surgery Addresses the Safety of Botox 2
Keeler Professional Combi Retinoscope with new slimline handle and lithium or dry cell option....
300XL System, English (U.K. cord), 100-240 VAC....
Micro-mini fiber optic light....
Xenon technology achieves a higher efficiency than halogen light sources. Consequently they provide more light....
Medicine Products: